Match!
Helle Linnebjerg
Eli Lilly and Company
46Publications
16H-index
957Citations
Publications 46
Newest
#1Tim HeiseH-Index: 46
#2Helle LinnebjergH-Index: 16
Last.Jennifer LeohrH-Index: 1
view all 12 authors...
1 CitationsSource
#1Helle LinnebjergH-Index: 16
Last.Jennifer LeohrH-Index: 1
view all 9 authors...
URLi is a novel prandial insulin lispro formulation developed to more closely match physiological insulin secretion. This randomized, double-blind, 2 period, crossover, 10 h euglycemic clamp study assessed PK and glucodynamics after one 15U SC dose of URLi and lispro in 41 patients with T1D (mean ± SD age, 32.0 ± 6.8 y; duration of T1D, 17.7 ± 9.3 y; HbA1c, 7.2 ± 0.6%; BMI, 24.8 ± 2.4 kg/m2). After dosing URLi, onset of insulin lispro appearance in the serum was faster (1.3 vs. 6.8 min; p Onset ...
Source
#1Jennifer LeohrH-Index: 1
#2Mary A. DellvaH-Index: 1
Last.Helle LinnebjergH-Index: 16
view all 11 authors...
URLi is a novel prandial insulin lispro formulation developed to more closely match physiological insulin secretion. This randomized, double-blind, 2 period, crossover, 10 hour euglycemic clamp study assessed the pharmacokinetics, glucodynamics and tolerability of insulin lispro after a single 15U SC dose of URLi and lispro (Humalog®) in 38 patients with T2D (mean [±SD] age, 60.0 ± 7.9 years; duration of diabetes, 17.4 ± 7.65 years; HbA1c, 7.4 ± 0.80%; BMI, 30.0 ± 2.97 kg/m2). After dosing URLi,...
Source
#1Tim HeiseH-Index: 46
#2Helle LinnebjergH-Index: 16
Last.Jennifer LeohrH-Index: 1
view all 11 authors...
URLi is a novel prandial insulin lispro formulation developed to more closely match physiological insulin secretion. This randomized, double-blind, 4-period, crossover study, compared the PK and glucodynamics (GD) of URLi, Humalog® (HL), NovoRapid® (NR) and Fiasp® (FA) after a test meal in 68 adults with T1D, after single individualized SC dose. Twelve healthy subjects provided the “normal” insulin secretory and glucose response to the test meal. URLi had the fastest insulin absorption: early ha...
Source
#1Xiaosu MaH-Index: 2
#2Charles BensonH-Index: 11
Last.Derek J. LeishmanH-Index: 19
view all 11 authors...
Source
#1Niels Porksen (Eli Lilly and Company)H-Index: 7
#2Helle Linnebjerg (Eli Lilly and Company)H-Index: 16
Last.Steven R. Smith (Translational Research Institute)H-Index: 70
view all 7 authors...
1 CitationsSource
#1Rakel Fuglsang Johansen (Aarhus University Hospital)H-Index: 2
#2Esben Søndergaard (Aarhus University Hospital)H-Index: 11
Last.Søren Nielsen (Aarhus University Hospital)H-Index: 60
view all 8 authors...
Aims In patients with type 1 diabetes, basal insulin peglispro (BIL) lowers weight and increases plasma triglycerides (TG) and hepatic fat relative to insulin glargine (GL). To explain this, we hypothesised that BIL's attenuated peripheral effects may include increased free fatty acid flux to the liver, causing increased VLDL-TG secretion and lipid oxidation, and decreased TG adipose tissue deposition. Materials and Methods In this open-label, randomised, 2-period crossover study, 14 patients wi...
3 CitationsSource
#1Xin Zhang (Eli Lilly and Company)H-Index: 4
#2Eric Chen Quin LamH-Index: 4
Last.Helle Linnebjerg (Eli Lilly and Company)H-Index: 16
view all 8 authors...
LY2963016 (LY IGlar) and Lantus (IGlar) are insulin glargine products with identical amino acid sequences. This was a phase 1 single-site, randomized, subject- and investigator-blinded, 4-treatment, 4-period crossover study to compare the pharmacokinetic (PK) and pharmacodynamic (PD) properties of LY IGlar and IGlar at 2 different doses. Fasted healthy subjects were randomly assigned to receive 2 single doses of LY IGlar and IGlar (0.3 and 0.6 U/kg for each product). Blood samples were collected...
2 CitationsSource
#1Niels Porksen (Eli Lilly and Company)H-Index: 7
#2Helle Linnebjerg (Eli Lilly and Company)H-Index: 16
Last.T. HeiseH-Index: 7
view all 11 authors...
Aims Basal insulin peglispro (BIL) is a novel PEGylated basal insulin with a flat pharmacokinetic and glucodynamic profile and reduced peripheral effects, which results in a hepato-preferential action. In Phase 3 trials, patients with T1DM treated with BIL had lower prandial insulin requirements, yet improved prandial glucose control, relative to insulin glargine (GL). We hypothesized that this may be due to an enhanced sensitivity to prandial insulin with BIL resulting from lower chronic periph...
Source
#1Helle Linnebjerg (Eli Lilly and Company)H-Index: 16
#2Eric Chen Quin LamH-Index: 4
Last.Tim HeiseH-Index: 46
view all 8 authors...
Aims LY2963016 (LY IGlar) and Lantus (IGlar) are insulin glargine products manufactured by distinct processes, but with identical amino acid sequences. This study compared the duration of action of LY IGlar and IGlar in subjects with type 1 diabetes mellitus (T1DM). Materials and methods This was a randomized, double-blind, single-dose, two-period, crossover study. Twenty subjects underwent 42-hour euglycaemic clamps after a single subcutaneous 0.3-U/kg dose of LY IGlar or IGlar. In this study, ...
11 CitationsSource
12345